Evaluation of the Patient With Prostate Cancer

Ashutosh Tewari, MD, MCh, Badrinath Konety, MD, Akshay Bhandari, MD, James Peabody, MD, Hans Stricker MD, Christine Johnson, PhD, Raymond Demers, MPH, Mani Menon, MD, FACS, the Josephine Ford Cancer Center and Department of Urology, Henry Ford Health System, Detroit, Michigan.

In This Article


It is clear that staging of prostate cancer is undergoing significant changes. Several new tests, markers, and imaging modalities are now available that can improve staging accuracy. Furthermore, there are many newer models available now that incorporate information from demographic, clinical, biochemical, imaging, systematic biopsy, and novel molecular markers into one unified predictive model. Neural network technology is also now available and seems very promising in predicting pathological stage using the abovementioned information. The exact role of these newer developments will be established by large, multicentric randomized trials comparing performance of these models. Once validated, these models will immensely help in patient management and in minimizing staging inaccuracy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.